Patients after percutaneous coronary intervention (PCI) with stent implantation and functional hyporesponsiveness to PY inhibitors are at higher risk of ischaemic events, particularly stent thrombosis (ST). It is currently not routine practice to assess the functional response to these agents. However, concern over functional hyporesponsiveness to clopidogrel has led to widespread uptake of prasugrel and ticagrelor as the default PY inhibitor after stent implantation in patients with acute coronary syndrome. Here we report, for the first time, 3 cases in which patients who have had ST exhibit hyporesponsiveness to clopidogrel, prasugrel, and ticagrelor.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075289 | PMC |
http://dx.doi.org/10.1155/2016/2096181 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!